# Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)

> **NCT00615927** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 64 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **DRUG:** Imatinib Mesylate & Hydroxyurea

## Key facts

- **NCT ID:** NCT00615927
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2009-04
- **Final completion:** 2012-06
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2013-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00615927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00615927, "Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00615927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*